Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER studyReport as inadecuate




Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study - Download this document for free, or read online. Document in PDF available to download.

Breast Cancer Research and Treatment

, Volume 143, Issue 3, pp 507–515

First Online: 11 January 2014Received: 03 December 2013Accepted: 23 December 2013DOI: 10.1007-s10549-013-2825-2

Cite this article as: de Dueñas, E.M., Hernández, A.L., Zotano, Á.G. et al. Breast Cancer Res Treat 2014 143: 507. doi:10.1007-s10549-013-2825-2

Abstract

The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 HER2, estrogen receptor ER and progesterone receptor PR between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent or metastatic breast cancer, either at first relapse or after successive disease progressions, who had an appropriately preserved sample from a primary tumor and were scheduled for a biopsy of the recurrent lesion, were included. Blinded determinations of receptor status on paired samples were performed by immunohistochemistry and fluorescence in situ hybridization at a central laboratory and compared with those performed locally. Overall, 196 patients were included and 184 patients were considered evaluable. Reasons for non-evaluability included the inability to perform biopsy n = 4 or biopsy results showing normal tissue n = 3, benign disease n = 3 or a second neoplasia n = 2. Conversion rates determined at local level were higher than those determined centrally HER2: 16 vs. 3 %, ER: 21 vs. 13 %, PR: 35 vs. 28 %, respectively. There was substantial agreement regarding the expression of HER2 in primary tumors and metastases, and ER at metastases, between local and central laboratories. PR at any site and ER at primary site showed moderate agreement. Oncologists altered their treatment plans in 31 % of patients whose tumor subtype had changed. These results reinforce the recommendation for performing confirmatory biopsies of metastases, not only to avoid misdiagnosis of breast cancer relapse, but also to optimize treatment clinicaltrials.gov identifier: NCT01377363.

KeywordsBreast neoplasm Conversion Hormone receptors HER2 Tumor markers Presented in part as a Poster at the 34th Annual San Antonio Breast Cancer Symposium SABCS on December 6–11, 2011.

Download fulltext PDF



Author: Eduardo Martínez de Dueñas - Ana Lluch Hernández - Ángel Guerrero Zotano - Ramón María Pérez Carrión - José Ig

Source: https://link.springer.com/







Related documents